MTOR and Alzheimer disease: The negation of cerebral hypoperfusion and neurovascular uncoupling during normative aging by mTOR attenuation [6] suggests that inhibitors of the mTOR pathway could potentially target the earliest stages of preclinical AD to prevent further deterioration of cerebral perfusion, effectively decelerating progression to AD [1].